IP Library › Granted Patent US 10,428,056
Granted Patent B2
US 10,428,056 · App. 16/113,635 · Granted Oct 1, 2019

Heterocyclic compound

Inventors: Takahiro Sugimoto (Kanagawa, JP); Shinkichi Suzuki (Kanagawa, JP); Hiroki Sakamoto (Kanagawa, JP); Masami Yamada (Kanagawa, JP); Minoru Nakamura (Kanagawa, JP); Makoto Kamata (Kanagawa, JP); Kenichiro Shimokawa (Kanagawa, JP); Masataka Murakami (Kanagawa, JP); Jinichi Yonemori (Kanagawa, JP); Takuto Kojima (Kanagawa, JP)
Assignee: Takeda Pharmaceutical Company Limited
C07D413/14A61P25/28C07D265/22C07D413/04C07D413/06C07D413/10C07D417/06C07D417/10C07D471/04C07D491/107C07F7/02C07F7/0814C07B2200/07
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,428,056
App. No.
16/113,635
Granted
Oct 1, 2019
Kind
B2
Abstract

The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.

Claims (2)

1. A method for treating Alzheimer's disease, schizophrenia, cognitive impairment associated with schizophrenia, pain, sleep disorder, Parkinson's disease dementia, Parkinson's disease, or dementia with Lewy bodies in a mammal, comprising: administering an effective amount of 8-chloro-6-((6-chloropyridin-3-yl)methyl)-3-((1S,2S)-2-hydroxycyclopentyl)-7-methyl-2,3-dihydro-4H-1,3-benzoxazin-4-one or a salt thereof to the mammal.

2. A method for treating Alzheimer's disease, schizophrenia, cognitive impairment associated with schizophrenia, pain, sleep disorder, Parkinson's disease dementia, Parkinson's disease, or dementia with Lewy bodies in a mammal, comprising: administering an effective amount of 3-((3S,4S)-4-hydroxytetrahydro-2H-pyran-3-yl)-7-methyl-6-(4-(1-methyl-1H-pyrazol-3-yl)benzyl)-2,3-dihydro-4H-1,3-benzoxazin-4-one or a salt thereof to the mammal.

Priority Claims (2)
JP 2015-129043 · Jun 26, 2015 · national
JP 2015-206797 · Oct 20, 2015 · national
Continuity (3)
Continuation 15799379 · Oct 31, 2017
Continuation 15190642 · Jun 23, 2016
Related Publication 20180362516A1 · Dec 20, 2018
Cited By (1)
US 12,378,256